Parkinson's Archives · BioBuzz

Bethesda’s Gain Therapeutics Presents New GBA1 Parkinson’s Disease Program Pre-clinical Data

<img width="300" height="300" src="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/Gain-Log-300x300.jpg?lossy=1&strip=1&webp=1" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image" alt="" decoding="async" srcset="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/Gain-Log-75x75.jpg?lossy=1&strip=1&webp=1 75w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/Gain-Log-150x150.jpg?lossy=1&strip=1&webp=1 150w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/Gain-Log.jpg?size=240x240&lossy=1&strip=1&webp=1 240w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/Gain-Log-300x300.jpg?lossy=1&strip=1&webp=1 300w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : May 3, 2021May 3, 2021 Published by : BioBuzz Media

Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model

Compounds are novel allosteric regulators that bind, stabilize and restore activity of mutated GCase

Compounds decrease both phosphorylated and aggregated α-synuclein levels in vitro and in vivo

Why The Next Biotech Boom Could be Sparked by New Therapies for Neurological Disorders

<img width="300" height="300" src="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2019/12/Copy-of-Featured-Images--300x300.jpg?lossy=1&strip=1&webp=1" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2019/12/Copy-of-Featured-Images--75x75.jpg?lossy=1&strip=1&webp=1 75w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2019/12/Copy-of-Featured-Images--100x100.jpg?lossy=1&strip=1&webp=1 100w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2019/12/Copy-of-Featured-Images--150x150.jpg?lossy=1&strip=1&webp=1 150w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2019/12/Copy-of-Featured-Images-.jpg?size=240x240&lossy=1&strip=1&webp=1 240w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2019/12/Copy-of-Featured-Images--300x300.jpg?lossy=1&strip=1&webp=1 300w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : December 3, 2019December 7, 2019 Published by : Sharlene Brown, PhD

Why The Next Biotech Boom Could be Sparked by New Therapies for Neurological Disorders Several Maryland Biotech Firms Are Blazing New Trails in Gene Therapy, Drugs and Diagnostics for Neurological [….]

3 Promising Maryland Biotechs that are Targeting Neurological Disorders

<img width="300" height="300" src="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2019/02/Brainscope-300x300.jpg?lossy=1&strip=1&webp=1" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2019/02/Brainscope-75x75.jpg?lossy=1&strip=1&webp=1 75w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2019/02/Brainscope-100x100.jpg?lossy=1&strip=1&webp=1 100w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2019/02/Brainscope-150x150.jpg?lossy=1&strip=1&webp=1 150w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2019/02/Brainscope.jpg?size=240x240&lossy=1&strip=1&webp=1 240w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2019/02/Brainscope-300x300.jpg?lossy=1&strip=1&webp=1 300w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : February 12, 2019April 2, 2019 Published by : Rajamani Selvam

3 Promising Maryland Biotechs that are Targeting Neurological Disorders BrainScope, AgeneBio and Neuraly February 13, 2019 Neurological disorders are diseases of the central nervous system such as Alzheimer’s and Parkinson’s. [….]